Thank you for visiting our website.
I am herewith sending you a message as the President of the Japanese Society of Clinical Neuropsychopharmacology (JSCNP).
The Executive Board elected me as the President for the 2019-20 term, and it is the second time for me to become the President since the 2013-14. Together with the officers and members of JSCNP I will once again do my best for the progress of the Society .
The JSCNP was founded in 1991 with the concise and clear objective "to develop clinical neuropsychopharmacology and improve pharmacotherapy in psychiatry". With vigorous activities performed by members who strongly supported the objective of the Society, the JSCNP has progressed steadily and became a corporation in 2010. The number of members has exceeded 1200. The Society has also brought up many prominent researchers including many professors and chairmen of psychiatry.
The major activities of the JSCNP include annual meeting, training and certification of the experts on clinical neuropsychopharmacology, awarding of the Paul Janssen Prize to the best articles in each year, scholarship to study abroad, publishing of the official journal Clinical Neuropsychopharmacology and Therapeutics (CNPT). The Textbook of Clinical Neuropsychopharmacology has been repeatedly published, currently as the third edition.
The research topics covered by the the Society are pharmacokinetics, pharmacodynamics, pharmacogenetics, treatment algorithms of psychiatric disorders, individualization and optimization of drug treatment, drug interactions, and so on. The most important mission of the JSCNP is to consider what is necessary to improve psychiatric drug treatment and to promote the research activities as they give us the fundamental basis. It is essential to deepen the understanding of not only "how to treat" but also "why drugs are effective", and to make use of it in clinical practice and further research.
In addition, there is an increasing expectation for the Society to educate and enlighten medical staff on psychiatric drug therapy. We established educational systems and have been engaged in developing human resources with special expertise from an early stage of the Society. We would like to strengthen such activities in the future.
Thank you for your understanding and support of the Society.
Toshiyuki Someya, M.D., Ph.D.
President, Japanese Society of Clinical Neuropsychopharmacology
Professor and Chair, Department of Psychiatry
Niigata University Graduate School of Medical and Dental Sciences